"The Eterna SCS System reflects our commitment to pioneering innovative technology in chronic pain management," said Pedro Malha, vice president, Neuromodulation, Abbott. Devices used for SCS consist of thin wires placed between the spinal cord and the vertebrae, and a small implant placed in the lower back that helps disrupt pain signals before they can reach the brain. SCS, also known as neurostimulation, has been recommended by doctors for more than 50 years 13 to help people manage chronic pain and improve quality of life. The Eterna SCS System is currently the smallest device available, *3 designed for implant site comfort, 11 and features Abbott’s BurstDR stimulation, which mimics natural firing patterns found in the brain 6 to deliver superior **12 pain relief over traditional tonic stimulation. Abbott designed the Eterna SCS System to be recharged wirelessly at a frequency of five times per year under normal use, 1,2 making it the lowest recharge burden platform on the market. The studies found that people wanted small, comfortable implants which don’t need to be charged daily. 10 The Canadian Medical Association Journal has also stated that the “increased awareness of and access to spinal cord stimulation therapy may allow more Canadians to benefit from relief of intractable chronic pain and may reduce opioid consumption.” 9Īpproved by Health Canada in 2023, Abbott developed the Eterna SCS System based on extensive studies with patients, physicians, and caregivers to understand the unmet needs of people living with chronic pain. 9 In addition, many candidates are only considered for SCS after standard pain treatment options have failed. "As the benefits of spinal cord stimulation technology become more widely understood and available, Abbott’s Eterna SCS System advances our options and ability to treat and relieve pain with this drug-free technology, giving patients a new lease on life and a greater sense of control.”Īccording to the Canadian Medical Association Journal, there is low awareness of SCS as an option for pain management. Michel Prud’homme, neurosurgeon from Hôpital de l'Enfant-Jésus hospital. "I witness the physical and mental toll of chronic pain on my patients, their relentless pursuit for relief, and the urgent need for new options,” shares Dr. 8 To tackle the negative impact of chronic pain, the Canadian Pain Task Force report calls for greater access to safe and effective treatment options, and more specialized pain services. 7 Additionally, unmanaged pain can lead to other health and societal issues, including mental health challenges and substance abuse. 6 Beyond the emotional and physical toll, chronic pain has profound economic implications with an estimated annual cost of $40 billion to the healthcare system and lost productivity. In Canada, one in five people aged 15 years and older live with chronic pain. The Eterna SCS system uses Abbott’s proprietary BurstDR (TM) stimulation, the only SCS technology with the highest level of clinical evidence (level 1A.) Abbott’s proprietary BurstDR™ therapy is proven to reduce pain by 23 per cent more than traditional tonic stimulation without the tingling sensation. The inaugural use case of the Eterna SCS system took place at Hôpital de l'Enfant-Jésus hospital in Quebec City, marking a significant milestone in the Canadian adoption of this technology by making it widely accessible for people suffering from chronic pain. MONTRÉAL, QC Ma-Abbott today announced that the company’s Eterna™ SCS system – the smallest implantable, rechargeable spinal cord stimulator (SCS) for the treatment of chronic pain,* 3,4 has been used for the first time in Canada. The device is the smallest implantable rechargeable spinal cord stimulator (SCS) *3 and provides the ability to deliver therapy while only requiring wireless recharging five times per year, 1,2 meaning less frequent charging for the chronic pain patients being treated.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |